These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 30197646)
1. Hepatitis C Virus Envelope Glycoproteins: A Balancing Act of Order and Disorder. Yost SA; Wang Y; Marcotrigiano J Front Immunol; 2018; 9():1917. PubMed ID: 30197646 [TBL] [Abstract][Full Text] [Related]
2. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1. Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563 [TBL] [Abstract][Full Text] [Related]
3. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2. Colbert MD; Flyak AI; Ogega CO; Kinchen VJ; Massaccesi G; Hernandez M; Davidson E; Doranz BJ; Cox AL; Crowe JE; Bailey JR J Virol; 2019 Jul; 93(14):. PubMed ID: 31068427 [TBL] [Abstract][Full Text] [Related]
4. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Flyak AI; Ruiz S; Colbert MD; Luong T; Crowe JE; Bailey JR; Bjorkman PJ Cell Host Microbe; 2018 Nov; 24(5):703-716.e3. PubMed ID: 30439340 [TBL] [Abstract][Full Text] [Related]
5. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs. McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001 [TBL] [Abstract][Full Text] [Related]
6. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes. Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE J Virol; 2018 May; 92(9):. PubMed ID: 29467319 [TBL] [Abstract][Full Text] [Related]
7. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine. Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595 [TBL] [Abstract][Full Text] [Related]
8. HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development. Ströh LJ; Krey T Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32947858 [TBL] [Abstract][Full Text] [Related]
9. Probing the Antigenicity of HCV Envelope Glycoproteins by Phage Display Antibody Technology. Giang E; Aleman F; Law M Methods Mol Biol; 2019; 1911():381-393. PubMed ID: 30593640 [TBL] [Abstract][Full Text] [Related]
11. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice. Zhu F; Wang Y; Xu Z; Qu H; Zhang H; Niu L; Xue H; Jing D; He H Mol Med Rep; 2019 Feb; 19(2):1016-1023. PubMed ID: 30569131 [TBL] [Abstract][Full Text] [Related]
12. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224 [TBL] [Abstract][Full Text] [Related]
13. N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses. Ren Y; Min YQ; Liu M; Chi L; Zhao P; Zhang XL Biochim Biophys Acta; 2016 Aug; 1860(8):1764-75. PubMed ID: 26278021 [TBL] [Abstract][Full Text] [Related]
14. Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens. Prentoe J; Janitzek CM; Velázquez-Moctezuma R; Goksøyr L; Olsen RW; Fanalista M; Augestad EH; Thrane S; Pihl AF; Gottwein JM; Sander AF; Bukh J PLoS One; 2021; 16(7):e0255336. PubMed ID: 34329365 [TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. Akazawa D; Moriyama M; Yokokawa H; Omi N; Watanabe N; Date T; Morikawa K; Aizaki H; Ishii K; Kato T; Mochizuki H; Nakamura N; Wakita T Gastroenterology; 2013 Aug; 145(2):447-55.e1-4. PubMed ID: 23673355 [TBL] [Abstract][Full Text] [Related]
16. A weak neutralizing antibody response to hepatitis C virus envelope glycoprotein enhances virus infection. Meyer K; Banerjee A; Frey SE; Belshe RB; Ray R PLoS One; 2011; 6(8):e23699. PubMed ID: 21887300 [TBL] [Abstract][Full Text] [Related]
17. Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C. Olbrich A; Wardemann H; Böhm S; Rother K; Colpitts CC; Wrensch F; Baumert TF; Berg T; Benckert J J Infect Dis; 2019 Aug; 220(7):1209-1218. PubMed ID: 31165162 [TBL] [Abstract][Full Text] [Related]
18. Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry. Prentoe J; Bukh J Front Immunol; 2018; 9():2146. PubMed ID: 30319614 [TBL] [Abstract][Full Text] [Related]
19. Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG. Logan M; Law J; Wong JAJ; Hockman D; Landi A; Chen C; Crawford K; Kundu J; Baldwin L; Johnson J; Dahiya A; LaChance G; Marcotrigiano J; Law M; Foung S; Tyrrell L; Houghton M J Virol; 2017 Jan; 91(1):. PubMed ID: 27795422 [TBL] [Abstract][Full Text] [Related]
20. Identification of a novel epitope in the C terminus of hepatitis C virus-E2 protein that induces potent and cross-reactive neutralizing antibodies. Das S; Mullick R; Kumar A; Tandon H; Bose M; Gouthamchandra K; Chandra M; Ravishankar B; Khaja MN; Srinivasan N; Das S; Melkote Subbarao S; Karande AA J Gen Virol; 2017 May; 98(5):962-976. PubMed ID: 28221101 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]